Disclosed is the use of a compound for manufacturing a medicament for treating age-related macular degeneration, where the compound is within the general formula depicted. Also disclosed are compositions comprising HPTP-beta inhibitors suitable for treating eye diseases and conditions. Examples of compounds disclosed are: 4-{ (S)-2-(4-Ethylthiazol-2-yl)-2-[(S)-2-(methoxycarbonylamino)-3-phenylpropanamido]ethyl} phenylsulfamic acid 4-{ (S)-2-[(5)-2-(Methoxycarbonylamino)-3-phenylpropanamido]-2-[4-(thiophen-2-yl)thiazol-2-yl] ethyl} pheaylsulfamic acid 4-{ (S)-2-[(S)-2-(Methoxycarbonylamino)-3-phenylpropanamido]-2-(2-ethylthiazol-4-y1) ethyl} phenylsulfamic acid and 4-{ (S)-2-[(S)-2-(Methoxycarbonylamino)-3-phenylpropanamido]-2-[2-(thiophen-2-yl)thiazol-4-yl]ethyl} phenylsulfamic acid. Further disclosed are methods for the treatment of diseases or conditions of the eye with HPTP-beta inhibitors, especially retinopathies, ocular edema and ocular neovascularization. Non-limiting examples of these diseases or conditions include diabetic macular edema, age-related macular degeneration (wet form), choroidal neovascularization, diabetic retinopathy, retinal vein occlusion (central or branch), ocular trauma, surgery induced edema, surgery induced neovascularization, cystoid macular edema, ocular ischemia, uveitis, and the like.
